According To A Trial Involving 20000 Participants, The Effectiveness Of The Russian Satellite V Vaccine Reached 92%.
2021-02-02 | by CusiGO
Russia’s sputnik-5 vaccine is gradually overcoming the widespread suspicion in the international scientific community. According to the preliminary results of a trial of 20000 participants published in the lancet on Tuesday, their two doses were 92% effective on covid. According to the accounts of the Russian direct investment fund, the vaccine has been registered in 16 countries – Belarus, Serbia, Argentina, Bolivia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, Iran, Guinea, Conakry, Tunisia, Armenia and the United Arab Emirates, The government agency that funded the drug research.
Scientists at the gamaleya Research Institute in Moscow stressed that their vaccine had a similar effect on people over the age of 60. Apart from fever and fatigue, no serious side effects were found on vaccinated people. Marie Paule Kieny, former director of vaccines and researcher of the World Health Organization, led a French scientific expedition to Russia last November to analyze Sputnik v. Covid, “Gini explained.
Of the 20000 subjects, 75% received two doses of the real vaccine, while the rest received two saline injections. The scientists detected 16 symptomatic patients (0.1%) in vaccinated population and 62 symptomatic patients (1.3%) in non vaccinated population, with an effective rate of 92%. The Russian trial will continue until there is data on 40000 participants.
“The development of the satellite-5 vaccine has been criticized for its haste, shortcut and lack of transparency. However, the published results are clear and the scientific principles of vaccination have been proved, This means that another vaccine can be combined with the fight to reduce the incidence of covid, “two independent British experts, Ian Jones of reading university and Polly Roy of London School of health and tropical medicine, commented in the lancet.
Sputnik V vaccine uses two human influenza adenoviruses modified by new coronavirus gene information. One adenovirus was injected first, and another enhancer was injected 21 days later. The vaccines from AstraZeneca and Oxford University also use adenovirus, but the common cold virus from chimpanzees, and announced that two full doses of the vaccine are 62% effective. Russian scientists believe that their strategy of using two different viruses will produce a stronger immune response.